We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
-4.89%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
-$114M
Cap. Flow
-$31M
Cap. Flow %
-2.92%
Top 10 Hldgs %
68.2%
Holding
44
New
2
Increased
8
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$110M
2
KRYS icon
Krystal Biotech
KRYS
+$14.3M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$13.9M
4
TARS icon
Tarsus Pharmaceuticals
TARS
+$5.56M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$4.16M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$77.2M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$28.3M
3
BCYC
Bicycle Therapeutics
BCYC
+$26.5M
4
PCVX icon
Vaxcyte
PCVX
+$12.1M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
2 Miscellaneous 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.04B
$180M 16.96%
8,434,232
– –
HLVX
2
DELISTED
HilleVax
HLVX
$101M 9.58%
+9,285,682
New +$110M
KRYS icon
3
Krystal Biotech
KRYS
$10.4B
$71.9M 6.79%
1,095,407
+229,157
+26% +$14.3M
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.12B
$69.4M 6.55%
3,566,912
– –
KDNY
5
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$62.9M 5.93%
3,595,026
+882,985
+33% +$13.9M
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.81B
$61.5M 5.8%
3,195,403
– –
PHAT icon
7
Phathom Pharmaceuticals
PHAT
$763M
$49.2M 4.64%
5,827,415
– –
SRRA
8
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$47.9M 4.52%
870,636
-1,471,562
-63% -$77.2M
IMGO
9
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$39.8M 3.75%
2,971,274
– –
PCVX icon
10
Vaxcyte
PCVX
$9B
$38.9M 3.67%
1,787,405
-522,149
-23% -$12.1M
CRNX
11
DELISTED
Crinetics Pharmaceuticals
CRNX
$26.4M 2.49%
1,414,823
– –
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.95B
$26.1M 2.46%
1,787,527
+370,370
+26% +$5.56M
ALPN
13
DELISTED
Alpine Immune Sciences Inc
ALPN
$25.4M 2.4%
2,985,757
-1,200,000
-29% -$10.3M
TCDA
14
DELISTED
Tricida, Inc. Common Stock
TCDA
$20.2M 1.9%
2,082,093
– –
COGT icon
15
Cogent Biosciences
COGT
$6.03B
$18.9M 1.78%
2,094,154
-557,600
-21% -$3.81M
ANAB icon
16
AnaptysBio
ANAB
$1.69B
$18.3M 1.72%
899,700
– –
GRCL
17
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$17.1M 1.62%
3,111,551
-334,422
-10% -$1.04M
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
$15.5M 1.46%
1,572,192
– –
MRUS
19
DELISTED
Merus
MRUS
$15.3M 1.44%
673,979
+45,000
+7% +$939K
FLACU
20
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$14.8M 1.4%
1,501,000
– –
REPL icon
21
Replimune Group
REPL
$1.39B
$14.1M 1.33%
806,267
+89,505
+12% +$1.47M
GRTS
22
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$12.7M 1.2%
5,237,348
– –
ARVN icon
23
Arvinas
ARVN
$598M
$12M 1.13%
285,331
+15,000
+6% +$753K
PASG icon
24
Passage Bio
PASG
$14.9M
$11.8M 1.12%
250,461
– –
VRDN icon
25
Viridian Therapeutics
VRDN
$2.63B
$11.3M 1.07%
980,302
-759,228
-44% -$10.2M
1
2

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q2 2022 Portfolio in Review

As of Q2 2022, Frazier Life Sciences Management held 44 positions worth $1.06B, down 9.7% from $1.17B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Frazier Life Sciences Management's Q2 2022 filing shows 2 new, 8 increased, 8 reduced and 3 closed positions. Its largest new stake was HilleVax: 9,285,682 shares worth $101M. The largest sale was Sierra Oncology, Inc. Common Stock, an estimated $77.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

  • Frazier Life Sciences Management's largest Q2 2022 buy was HilleVax: 9,285,682 shares worth $101M.
  • Frazier Life Sciences Management added most to Krystal Biotech in Q2 2022, an estimated $14.3M increase.
  • Frazier Life Sciences Management's biggest Q2 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $77.2M.
  • Frazier Life Sciences Management fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $26.5M.
  • Frazier Life Sciences Management's ten largest holdings make up 68% of its $1.06B portfolio in Q2 2022.
  • Frazier Life Sciences Management opened 2 new positions and closed 3 in Q2 2022.
  • Frazier Life Sciences Management's portfolio value fell 9.7% quarter-over-quarter to $1.06B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2022, filed 10 Aug 2022.